After Spiking During COVID-19, CLIA Lab Formation on the Decline, CMS Data Shows
Home > About Us > News & Events > After Spiking During COVID-19, CLIA Lab Formation on the Decline, CMS Data Shows
After Spiking During COVID-19, CLIA Lab Formation on the Decline, CMS Data Shows
October 11, 2024
LEAP Managing Partner Josh Kramer recently sat with 360DX GenomeWeb editor Adam Bonislawski talking about current trends in a post-COVID clinical laboratory market. Bonislawski quoted Josh as saying he is seeing lab formation is in testing aimed narrowly at specific diseases or clinical pathways: “Disease-focused laboratories are popping up consistently and catering to a niche audience,” he said. “They may not even have a unique assay. They may just have unique positioning and a unique service offering.’
Kramer said he also continues to see molecular pathologists and cytopathologists launching their own laboratories, “taking that small percentage of a fragmented market that they can, and it's enough for them.”
“We still see $25 million labs opening their doors," he said. "Even $6 million labs are opening their doors.”
This particular article about the current state of CLIA lab formation is worth your time, although it is behind a paywall.
You can find more of Adam’s work here.
And if you’d like to talk to Josh directly about what he’s seeing in clinical labs and laboratory science, including, LIMS, LDTs, Lab Automation, Lab informatics, Workflows, and more, contact us and let’s talk.